基于生物信息学数据库探讨FOXO3基因在膀胱癌中的表达及临床意义

doi:10.3969/j.issn.1004-616x.2020.05.008

Abstract

Abstract: OBJECTIVE: To use a bioinformatics database for determining expression levels and clinical significance of FOXO3 in bladder cancer (BLCA). METHODS: The GEPIA databases were used to analyze the expression of FOXO3 gene in bladder cancer and normal bladder tissues. In addition,the RNA-Seq data and clinical data were downloaded from the UALCAN database and were used to determine correlations between FOXO3 gene expression and prognosis. TIMER was used to investigate correlations between FOXO3 and cancer immune infiltrate cells. The String database was used to identify proteins which interact with FOXO3. RESUITS: Based on analyses of the GEPIA database,expression of FOXO3 gene in bladder cancer tissues was significantly lower than that in normal tissues(P < 0.01). In addition,the low expression was significantly associated with longer and disease-free survival in patients than the high expression(all P < 0.05). Analyses of the TIMER database show that the FOXO3 expression had a positive correlation with infiltrating levels of B cells (r=0.12,P < 0.05),CD8⁺ T cells (r=0.262,P < 0.01),CD4⁺ T cells (r=0.12,P < 0.05),macrophages (r=0.252,P < 0.01),neutrophils (r=0.242,P < 0.01) and dendritic cells (r=0.162,P < 0.01) in bladder cancers. Analyses of protein-protein interactions reveal that AKT1,SIRT1,EP300,BCL2L11,SOD2,SGK1,AKT2,CREBBP,CDKN1B and SMAD4 interacted with FOXO3. CONCLUSION: Our findings demonstrate that the FOXO3 gene was expressed at low levels in bladder cancer tissues. However,high FOXO3 expression was correlated with poor prognosis of bladder cancer and was correlated with infiltrating levels of immune cells in bladder cancer.

Key words: bladder cancer, FOXO3, database, expression, diagnosis

CLC Number:

R737.14

TAO Yan, LI Lanlan, LU Jianzhong, LIU Shanhui, FU Shengjun, ZHANG Jing. Expression and clinical significance of FOXO3 gene in bladder cancer based on bioinformatics database[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 374-379.

References

[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2018[J]. CA:A Cancer J Clin, 2018, 68(1):7-30.
[2] ZIGEUNER R. News in diagnosis, treatment, and risk group assessment[J]. Nat Rev Urol, 2017, 14(2):74.
[3] LINK W. Introduction to FOXO biology[J]. Methods Mol Biol Clifton N J, 2019, 1890:1-9.
[4] LIU Y, AO X, DING W, et al. Critical role of FOXO3a in carcinogenesis[J]. Mol Cancer, 2018, 17(1):1-12.
[5] LALLEMAND F, VACHER S, DE KONING L, et al. The high protein expression of FOXO3, but not that of FOXO1, is associated with markers of good prognosis[J]. Sci Rep, 2020, 10:6920.
[6] SONG S S, YING J F, ZHANG Y N, et al. High expression of FOXO3 is associated with poor prognosis in patients with hepatocellular carcinoma[J]. Oncol Lett, 2020, 19(4):3181-3188.
[7] ZHOU J, ZHOU L Y, TANG X, et al. Circ-Foxo3 is positively associated with the Foxo3 gene and leads to better prognosis of acute myeloid leukemia patients[J]. BMC Cancer, 2019, 19(1):930.
[8] TANG Z F, LI C W, KANG B X, et al. GEPIA:a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(W1):W98-W102.
[9] CHANDRASHEKAR D S, BASHEL B, BALASUBRAMANYA S A H, et al. UALCAN:a portal for facilitating tumor subgroup gene expression and survival analyses[J]. Neoplasia, 2017, 19(8):649-658.
[10] LI T W, FAN J Y, WANG B B, et al. TIMER:a web server for comprehensive analysis of tumor-infiltrating immune cells[J]. Cancer Res, 2017, 77(21):e108-e110.
[11] SHAN Z F, LI Y W, YU S Q, et al. CTCF regulates the FoxO signaling pathway to affect the progression of prostate cancer[J]. J Cell Mol Med, 2019, 23(5):3130-3139.
[12] AN Y F, WANG B, WANG X, et al. SIRT1 inhibits chemoresistance and cancer stemness of gastric cancer by initiating an AMPK/FOXO3 positive feedback loop[J]. Cell Death Dis, 11(2):115.
[13] LIU C, ZHAO Y, WANG J N, et al. FoxO3 reverses 5-fluorouracil resistance in human colorectal cancer cells by inhibiting the Nrf2/TR1 signaling pathway[J]. Cancer Lett, 2020, 470:29-42.
[14] QIAN Z R, REN L, WU D C, et al. Overexpression of FoxO3a is associated with glioblastoma progression and predicts poor patient prognosis[J]. Int J Cancer, 2017, 140(12):2792-2804
[15] YU D S, CHEN Y T, WU C L, et al. Expression of p-FOXO3/FOXO3 in bladder cancer and its correlation with clinicopathology and tumor recurrence[J]. Int J Clin Exp Pathol, 2017, 10(11):11069-11074.
[16] YU C P, ZHANG Z L, LIAO W T, et al. The tumor-suppressor gene Nkx2.8 suppresses bladder cancer proliferation through upregulation of FOXO3a and inhibition of the MEK/ERK signaling pathway[J]. Carcinogenesis, 2012, 33(3):678-686.
[17] LI J L, MA W L, CHENG X M, et al. Activation of FOXO3 pathway is involved in polyphyllin I-induced apoptosis and cell cycle arrest in human bladder cancer cells[J]. Arch Biochem Biophys, 2020, 687:108363.
[18] 杨凯莉, 孙昭, 白春梅, 等. 单细胞RNA测序技术在肿瘤免疫微环境研究中的应用[J]. 中国医学科学院学报, 2020, 42(1):117-123.
[19] CABRERA-ORTEGA A A, FEINBERG D, LIANG Y D, et al. The role of forkhead box 1(FOXO1) in the immune system:dendritic cells, T cells, B cells, and hematopoietic stem cells[J]. Crit Rev Immunol, 2017, 37(1):1-13.
[20] BARETTI M, LE D T. DNA mismatch repair in cancer[J]. Pharmacol Ther, 2018, 189:45-62.
[21] DAS T P, SUMAN S, ALATASSI H, et al. Inhibition of AKT promotes FOXO3a-dependent apoptosis in prostate cancer[J]. Cell Death Dis, 2016, 7(2):e2111.
[22] LIANG Z, WANG X, XU X, et al. microRNA-608 inhibits proliferation of bladder cancer via AKT/FOXO3a signaling pathway[J]. Mol Cancer, 2017, 16(1):1-13.
[23] MAHMUD Z, GOMES A R, LEE H J, et al. EP300 and SIRT1/6 Co-regulate lapatinib sensitivity via modulating FOXO3-acetylation and activity in breast cancer[J]. Cancers, 2019, 11(8):1067.
[24] LIU W W, WANG X C, LIU Z P, et al. SGK1 inhibition induces autophagy-dependent apoptosis via the mTOR-Foxo3a pathway[J]. Br J Cancer, 2017, 117(8):1139.
[25] CUI C, HAN S S, YIN H D, et al. FOXO3 is expressed in ovarian tissues and Acts as an apoptosis initiator in granulosa cells of chickens[J]. Biomed Res Int, 2019, 2019:6902906.
[26] ZHAO X L, PETURSSON F, VIOLLET B, et al. Peroxisome proliferator-activated receptor γ coactivator 1α and FoxO3A mediate chondroprotection by AMP-activated protein kinase[J]. Arthritis Rheumatol, 2014, 66(11):3073-3082.
[27] LU H H, ZHANG L H, YANG L, et al. The PI3K/Akt/FOXO3a pathway regulates regeneration following spinal cord injury in adult rats through TNF-α and p27kip1 expression[J]. Int J Mol Med, 2018, 41(5):2832-2838.

Expression and clinical significance of FOXO3 gene in bladder cancer based on bioinformatics database

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	PENG Youbin, LIN Hao, LI Ming, HUANG Haihua. Expression of TPX2 and its clinicalsignificance in non-muscle-invasive bladder cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 30-34.
[2]	YU Xinlu, YU Bing, WANG Chen, ZHANG Hongxia, ZHU Haiying. Induction of hepatic stem-like cells from mouse embryonic fibroblasts using tetracycline-controlled Hnf1β and Foxa3 expression vectors [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 163-171.
[3]	LUO Jiao, ZHANG Kunchi, ZHOU Li. Analysis of differentially expressed microRNAs between the triple negative breast cancer cell line MDA-MB-231 and its brain metastasis cell line [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 218-224.
[4]	WANG Yaokun, CHEN Juexiao, ZHANG Mingyuan, SHAO Changli, YANG Yu, SHANG Yu. Database analysis of genome variations and targeted drug screening of anaplastic thyroid cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 53-57.
[5]	LI Jinglei, HOU Wei. ceRNA network-based stigmasterolintervention on lung squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 423-429.
[6]	SHI Hailin, HE Tianji, LIU Feng, CAI Menghui, GE Bo. Prognostic value of TCGA-database mutation burden in muscle-invasive bladder cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 430-437,443.
[7]	DU Qiang, YAO Yiyong, ZENG Gang. Expression and clinical significance of ASPM in lung adenocarcinoma according to the TCGA database [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 457-463.
[8]	XU Haiming, LIU Keliang, HAO Yanxing, WANG Ling, LIU Zhihong, DE Xiaoming. Usefulness of combined application of biomarkers in early auxiliary diagnosis of silicosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 395-397,401.
[9]	QIN Shuangjian, LI Boru, CAI Ying, ZHENG Kai, WANG Bingyu, LI Runbing, XIAO Fang, ZENG Ming, XU Xinyun. PM_2.5 exposure on expression of oncogenes and apoptosis genes in hepatocytes [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(4): 281-285.
[10]	ZHANG Huijuan, HUANG Dayuan, ZHANG Jie, TANG Haiou, XIE Anxin, TAN Dunyong. Effects of SF1a-PRLR and ΔS2 SF1a-PRLR on proliferation and microRNA expressionin MCF-7 breast cancer cell [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 203-208.
[11]	XU Xiaoyuan, LI Wenli, XU Lan, LI Rui. Expression of VP1 from enterovirus 71 and coxsackievirus A16 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(1): 43-46,51.
[12]	XIONG Qiang, JIANG Xiaoyan, DING Lixin, LIU Xiaodan, ZHOU Pingkun, DING Kuke. Expression and identification of human IER5 in an insect baculovirus expression system [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(1): 57-61,66.
[13]	LI Shuang, LU Xue, FENG Jiangbin, TIAN Mei, CAI Tianjing, LIU Qingjie. Effects of gender and age on expression of radiation-responsive genes in irradiated human peripheral blood samples [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(6): 421-427.
[14]	GAO Jie, ZHANG Xiao, WEI Chao. Involvement of differentially expressed miRNA in prognosis of pancreatic cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(3): 173-179.
[15]	LIU Ying, WANG Ke, HE Yangting, XIAO Jinrong, WANG Huanzhuo, LI Yangkai, WEI Sheng. Prognosis-associated lncRNA signature in lung squamous cell carcinomas based on TCGA database [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(6): 468-472,478.